DK0439265T3 - Hidtil ukendte 1,3-dicarbonylforbindelser og anvendelse deraf - Google Patents

Hidtil ukendte 1,3-dicarbonylforbindelser og anvendelse deraf

Info

Publication number
DK0439265T3
DK0439265T3 DK91300224.2T DK91300224T DK0439265T3 DK 0439265 T3 DK0439265 T3 DK 0439265T3 DK 91300224 T DK91300224 T DK 91300224T DK 0439265 T3 DK0439265 T3 DK 0439265T3
Authority
DK
Denmark
Prior art keywords
new
dicarbonyl compounds
antiallergy
carbamyl
lipoxygenase
Prior art date
Application number
DK91300224.2T
Other languages
Danish (da)
English (en)
Inventor
Fumitaka Ito
Toshihide Kokura
Kazunari Nako
Masami Nakane
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK0439265T3 publication Critical patent/DK0439265T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/40Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/82Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/527Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings
    • C07C49/573Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings containing hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C07C49/835Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups having unsaturation outside an aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK91300224.2T 1990-01-22 1991-01-11 Hidtil ukendte 1,3-dicarbonylforbindelser og anvendelse deraf DK0439265T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012342A JPH0717589B2 (ja) 1990-01-22 1990-01-22 新規1,3―ジカルボニル化合物およびその組成物

Publications (1)

Publication Number Publication Date
DK0439265T3 true DK0439265T3 (da) 1994-05-02

Family

ID=11802612

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91300224.2T DK0439265T3 (da) 1990-01-22 1991-01-11 Hidtil ukendte 1,3-dicarbonylforbindelser og anvendelse deraf

Country Status (11)

Country Link
US (1) US5166161A (fr)
EP (1) EP0439265B1 (fr)
JP (1) JPH0717589B2 (fr)
AT (1) ATE103270T1 (fr)
CA (1) CA2034546C (fr)
DE (1) DE69101449T2 (fr)
DK (1) DK0439265T3 (fr)
ES (1) ES2062678T3 (fr)
FI (1) FI910300A (fr)
IE (1) IE63709B1 (fr)
PT (1) PT96529B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992002514A1 (fr) * 1990-07-27 1992-02-20 Chugai Seiyaku Kabushiki Kaisha Nouveau derive de benzopyrane
US5514675A (en) * 1994-10-20 1996-05-07 Eli Lilly And Company Naphthyl bradykinin receptor antagonists
WO1996041626A1 (fr) * 1995-06-12 1996-12-27 G.D. Searle & Co. Compositions comprenant un inhibiteur de cyclooxygenase-2 et un inhibiteur de 5-lipoxygenase
WO1997048694A1 (fr) 1996-06-20 1997-12-24 Board Of Regents, The University Of Texas System Composes et procedes d'obtention de preparations pharmacologiquement actives et leurs utilisations
JP2003155231A (ja) * 2001-11-20 2003-05-27 Kikkoman Corp 医薬及び抗アレルギー剤
FR2854158B1 (fr) * 2003-04-25 2006-11-17 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
DE10347386B4 (de) 2003-10-08 2006-05-24 Schering Ag Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
US7662821B2 (en) 2003-10-08 2010-02-16 Bayer Schering Pharma Ag Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US7638515B2 (en) 2003-10-08 2009-12-29 Bayer Schering Pharma Aktiengesellschaft Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
WO2005034939A1 (fr) 2003-10-08 2005-04-21 Schering Aktiengesellschaft Derives de tetrahydronaphtalene a substitution 1-amino-2-oxy, procedes pour leur production et leur utilisation en tant qu'anti-inflammatoires
US20080153859A1 (en) 2004-04-05 2008-06-26 Hartmut Rehwinkel Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
WO2006054912A1 (fr) * 2004-11-18 2006-05-26 Obchestvo S Ogranichennoy Otvetstvennost'u 'asineks Medhim' Derives d'aryl(hetaryl)-3-aminomethylchinolone-2 utilises en tant qu'inhibiteurs de no-synthetase et de cyclo-oxygenase-2, procedes de leur fabrication et compositions pharmaceutiques sur leur base
EP1834948A1 (fr) 2006-03-15 2007-09-19 Bayer Schering Pharma Aktiengesellschaft Derives de tetrahydronaphtalene , procedes pour leur production et leur utilisation en tant qu'anti-inflammatoires
KR20100122944A (ko) * 2008-03-01 2010-11-23 메르크 파텐트 게엠베하 당뇨병 타입 1 및 2를 치료 및 예방하기 위한 5-옥소-2,3,4,5-테트라하이드로-벤조[b]옥세핀-4-카르복실산 아미드 및 2,3-디하이드로-벤조[b]옥세핀-4-카르복실산 아미드

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3591584A (en) * 1968-08-27 1971-07-06 Pfizer Benzothiazine dioxides
US3829446A (en) 1970-10-15 1974-08-13 Pfizer Oxobenzofuran intermediates
US3749731A (en) 1971-07-08 1973-07-31 Warner Lambert Co 2-oxo-n-(2-thiazolyl)-3-indoline-carboxamide
US4400543A (en) * 1975-10-28 1983-08-23 Eli Lilly And Company 3-Phenyl-4-benzoyl-1,2-dihydronaphthalenes
DE2646213A1 (de) * 1975-10-28 1977-05-12 Lilly Co Eli Aroylphenylnaphthaline und verfahren zu ihrer herstellung
PT66412B (en) 1976-04-09 1978-09-15 Ciba Geigy Ag Process for the manufacture of new oxothia compounds
GB8325370D0 (en) * 1983-09-22 1983-10-26 Fujisawa Pharmaceutical Co Benzoxazoline and benzothiazoline derivatives
US4686224A (en) 1984-10-31 1987-08-11 Pfizer Inc. Oxindole antiinflammatory agents

Also Published As

Publication number Publication date
IE63709B1 (en) 1995-05-31
FI910300A (fi) 1991-07-23
US5166161A (en) 1992-11-24
PT96529B (pt) 1998-07-31
ES2062678T3 (es) 1994-12-16
FI910300A0 (fi) 1991-01-21
ATE103270T1 (de) 1994-04-15
CA2034546A1 (fr) 1991-07-23
IE910185A1 (en) 1991-07-31
EP0439265B1 (fr) 1994-03-23
JPH0717589B2 (ja) 1995-03-01
CA2034546C (fr) 1997-02-11
DE69101449T2 (de) 1994-07-14
JPH03220165A (ja) 1991-09-27
EP0439265A1 (fr) 1991-07-31
PT96529A (pt) 1991-10-15
DE69101449D1 (de) 1994-04-28

Similar Documents

Publication Publication Date Title
DK0439265T3 (da) Hidtil ukendte 1,3-dicarbonylforbindelser og anvendelse deraf
DK0544821T3 (da) Indolderivater som antiallergiske og antiinflammatoriske midler
EG19649A (en) Substituted phthalides and heterocyclic phthalides and their use as herbicide
DE69013836D1 (de) Benzimidazolverbindungen und deren Anwendung.
DE59510421D1 (de) Substituierte Pyridylpyrazole
ES2088076T3 (es) Piperacinil- y piperidinilciclohexanoles.
NO911231D0 (no) Fremgangsmaate for fremstilling av 3,5-di-tert. butyl-4-hydroksyfenylmetylen-derivater av 2-substituerte tiazolidinoner, oksazolidinoner og imidazolidinoner.
DE69011305D1 (de) Cyclopropylderivate als Lipoxygenase-Inhibitoren.
PT86785A (pt) Novel naphthalene derivatives having use as antiallergy and antiinflammatory agents
FI900041A (fi) Substituerade indol-, benzofuran- och benzotiopenderivat saosom 5-lipoxigenasinhibitorer,
MX9306814A (es) Nuevas 5-(amino n-heterosubstituidos) quinolonas antimicrobianas.
DK0531116T3 (da) Herbicide sammensætninger
ATE194332T1 (de) Arylindazoline und ihre anwendung als herbizide
ATE66221T1 (de) Substituierte 5-amino-pyrazole und diese enthaltende fungizide.
ATE91234T1 (de) Verwendung von dimetylheptylphenylbutanoylethanolamin bei der behandlung von hyperuricemie.